CardioSource WorldNews | Page 52

1

#

PRESCRIBED
NOAC IN THE US*1

†2-13

IMPORTANT SAFETY INFORMATION (cont’d)
OVERDOSAGE
Discontinue XARELTO® and initiate appropriate
therapy if bleeding complications associated with
overdosage occur. A specific antidote for rivaroxaban is
not available. The use of activated charcoal to reduce

absorption in case of XARELTO® overdose may be
considered. Due to the high plasma protein binding,
rivaroxaban is not dialyzable.

ADVERSE REACTIONS IN CLINICAL STUDIES
The most common adverse reactions with
XARELTO® were bleeding complications.

*Among Factor Xa inhibitor
orss an
andd di
direct thrombin inhibitors.
†
Based on the follow
win
ingg re
regi
gist
striies, claims databases, and studies: Optum Labs=16,253; IMS Health LifeLink=1,649; Truven Health=55,5563
63;; Daani
n sh reg
egis
istr
try=
y=1,
1,30
303;
3;
XAMOS=8,
8,77
778;
8; Sym
ymph
p ony=3,654; ORTHO-TEP=1,043; Japanese registry=1,035; Dresden NOAC=1,776; XALIA=2
=2,505; DOD database=27,4667; XAN
ANTU
TUS=
S=6,
6,7884.

Please see Important Safety Information on preceding pages.
Please see accompanying Brief Summary of full Prescribing Information,
including Boxed WARNINGS, on preceding pages, or visit www.XareltoHCP.com/PI.
XARELTO® is licensed from Bayer HealthCare AG, 51368 Leverkusen, Germany.
© Janssen Pharmaceuticals, Inc. 2016
June 2016
047169-160523

Janssen Pharmaceuticals, Inc.

052840-160508

Published safety outcomes in real-world patients,
from observational studies